Cargando…
Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA...
Autores principales: | Rohon, Peter, Vondrakova, Jana, Jonasova, Anna, Holzerova, Milena, Jarosova, Marie, Indrak, Karel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420792/ https://www.ncbi.nlm.nih.gov/pubmed/22937326 http://dx.doi.org/10.1155/2012/369086 |
Ejemplares similares
-
5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011) -
Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
por: Kreutzman, Anna, et al.
Publicado: (2011) -
Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia
por: Zack, Marie-Therese, et al.
Publicado: (2022) -
Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report
por: Pelkey, Lauren J, et al.
Publicado: (2022) -
Lysozyme nephropathy in chronic myelomonocytic leukemia
por: Patel, Ami B., et al.
Publicado: (2019)